$SAN #Sanofi Sanofi : Positive result for Libtayo in monotherapy in NSCLC: &gt;Libtayo trial in monotherapy in NSCLC is one year ahead of schedule - What we knew was reconfirmed yesterday, not all anti-PD1s are equivalent and significant… https://t.co/Lt7aapEoMW #equity #stocks https://t.co/DxeVWQos6q